CD36: a key mediator of resistance to HER2 inhibitors in breast cancer

William W Feng; Scott Bang; Manabu Kurokawa

doi:10.1080/23723556.2020.1715766

CD36: a key mediator of resistance to HER2 inhibitors in breast cancer

Mol Cell Oncol. 2020 Jan 23;7(2):1715766. doi: 10.1080/23723556.2020.1715766. eCollection 2020.

Authors

William W Feng^{1

2}, Scott Bang¹, Manabu Kurokawa^{1

2}

Affiliations

¹ Department of Biological Sciences, Kent State University, Kent, OH, USA.
² Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

Abstract

Acquired resistance to anti-HER2 therapy is a significant clinical challenge in breast cancer. We recently discovered that during acquisition of resistance to HER2 inhibition, upregulation of the fatty acid transporter CD36 takes place, playing a key role in metabolic rewiring and resistance to anti-HER2 therapy.

Keywords: FASN; FATP; lapatinib; lipid metabolism; trastuzumab.

Abstract

Grants and funding